XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements (Tables)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Collaboration Revenue
Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Takeda Collaboration Agreement(1)
$4,425 $9,271 $18,597 $17,826 
Sanofi Collaboration Agreement
Peripheral Program License— — 15,000 — 
   Retained Activities— 117 — 925 
   Alzheimer's Disease Services(2)
— 5 4 93 
Total Sanofi Collaboration Revenue— 122 15,004 1,018 
Biogen Collaboration Agreement
Option Research Services(2)
860 — 2,546 — 
Total Biogen Collaboration Revenue$860 $— $2,546 $— 
Total Collaboration Revenue$5,285 $9,393 $36,147 $18,844 
_________________________________________________
(1)$15.6 million of revenue for the nine months ended September 30, 2021 was included in the contract liability balance at the beginning of the period. All revenue for the three months ended September 30, 2021 and the three and nine months ended September 30, 2020 was included in the contract liability balance at the beginning of the period.
(2)Revenue for the three and nine months ended September 30, 2021 and September 30, 2020, where applicable, represent amounts that were included in the contract liability balance at the beginning of the respective period.